Quick Answer
LIPELLA PHARMACEUTICALS INC. reported Total Revenue of $536.4 thousand for fiscal year 2024.
LIPELLA PHARMACEUTICALS INC. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $536.4K +19.3% |
$449.6K +144.2% |
$184.2K -29.0% |
$259.3K | — |
| Net Income | -$5.02M -8.6% |
-$4.62M -77.8% |
-$2.60M -39.3% |
-$1.87M | — |
| Diluted EPS | -$4.79 +22.2% |
-$6.16 -862.5% |
-$0.64 -16.4% |
-$0.55 | — |
| Total Assets | $2.67M -25.3% |
$3.58M -39.9% |
$5.95M +195.6% |
$2.01M | — |
| Cash and Equivalents | $2.18M -33.7% |
$3.29M -35.7% |
$5.12M +262.3% |
$1.41M | — |
| Stockholders Equity | $1.92M -39.0% |
$3.14M -32.7% |
$4.68M +228.4% |
$1.42M +207.3% |
$463.3K |
| R&D Expense | $3.61M +18.9% |
$3.04M +19.3% |
$2.55M +74.9% |
$1.46M | — |
| Operating Income | -$5.08M -7.0% |
-$4.75M -83.3% |
-$2.59M -35.2% |
-$1.92M | — |
| Shares Outstanding | 1.21M +59.8% |
756,743 -86.8% |
5.74M +48.6% |
3.87M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2025 | $86.7K | -36.4% | -33.0% |
| Net Income | September 30, 2025 | -$1.25M | +13.2% | +5.5% |
| Diluted EPS | September 30, 2025 | -$0.28 | +78.3% | +9.7% |
| Total Assets | September 30, 2025 | $2.35M | +8.8% | -36.8% |
| Cash and Equivalents | September 30, 2025 | $1.86M | +37.1% | -33.3% |
| Stockholders Equity | September 30, 2025 | $1.49M | +2.0% | -45.7% |
| R&D Expense | September 30, 2025 | $721.0K | -31.1% | -8.9% |
| Operating Income | September 30, 2025 | -$1.27M | +12.7% | +6.1% |
| Shares Outstanding | September 30, 2025 | 4.62M | +323.5% | +3.4% |
- LIPELLA PHARMACEUTICALS INC. reported Total Revenue of $536.4 thousand for fiscal year 2024.
- LIPELLA PHARMACEUTICALS INC. showed an increase of +19.3% in Total Revenue compared to the prior fiscal year.
- LIPELLA PHARMACEUTICALS INC. reported Net Income of -$5.02 million for fiscal year 2024.
- LIPELLA PHARMACEUTICALS INC. showed a decrease of -8.6% in Net Income compared to the prior fiscal year.
- LIPELLA PHARMACEUTICALS INC. reported Diluted EPS of $4.79 per share (loss) for fiscal year 2024.
- LIPELLA PHARMACEUTICALS INC. showed an increase of +22.2% in Diluted EPS compared to the prior fiscal year.
- LIPELLA PHARMACEUTICALS INC. reported Total Assets of $2.67 million for fiscal year 2024.
- LIPELLA PHARMACEUTICALS INC. showed a decrease of -25.3% in Total Assets compared to the prior fiscal year.
- LIPELLA PHARMACEUTICALS INC. reported Cash and Equivalents of $2.18 million for fiscal year 2024.
- LIPELLA PHARMACEUTICALS INC. showed a decrease of -33.7% in Cash and Equivalents compared to the prior fiscal year.
- LIPELLA PHARMACEUTICALS INC. reported Stockholders Equity of $1.92 million for fiscal year 2024.
- LIPELLA PHARMACEUTICALS INC. showed a decrease of -39.0% in Stockholders Equity compared to the prior fiscal year.
- LIPELLA PHARMACEUTICALS INC. reported R&D Expense of $3.61 million for fiscal year 2024.
- LIPELLA PHARMACEUTICALS INC. showed an increase of +18.9% in R&D Expense compared to the prior fiscal year.
- LIPELLA PHARMACEUTICALS INC. reported Operating Income of -$5.08 million for fiscal year 2024.
- LIPELLA PHARMACEUTICALS INC. showed a decrease of -7.0% in Operating Income compared to the prior fiscal year.
- LIPELLA PHARMACEUTICALS INC. reported Shares Outstanding of 1.21 million shares for fiscal year 2024.
- LIPELLA PHARMACEUTICALS INC. showed an increase of +59.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: